This week's roundup of Houston innovators includes Omair Tariq of Cart.com, Amanda Marciel of Rice University, and Youngro Lee of Brassica. Photos courtesy

Editor's note: Welcome to another Monday edition of Innovators to Know. Today I'm introducing you to three Houstonians to read up about — three individuals behind recent innovation and startup news stories in Houston as reported by InnovationMap. Learn more about them and their recent news below by clicking on each article.


Omair Tariq, co-founder and CEO of Cart.com

Omair Tariq of Cart.com joins the Houston Innovators Podcast to share his confidence in Houston as the right place to scale his unicorn. Photo via Cart.com

Last November, Houston-founded logistics tech company Cart.com announced that it would be returning its headquarters to Houston after spending the last two years growing in Austin. But Co-Founder and CEO Omair Tariq says that while the corporate address may have changed, he actually never left.

"I've been in Houston now forever — and I don't think I'm planning on leaving anytime soon. I love Houston — this city has given me everything I have," Tariq says on the Houston Innovators Podcast. "I even love the traffic and everything people hate about Houston."

Tariq, who was born in Pakistan and grew up in Dubai before relocating as a teen to Houston, shared his entrepreneurial journey on the show, which included starting a jewelry business and being an early employee at Blinds.com before it was acquired in 2014 by Home Depot. Continue reading.

Amanda Marciel, the William Marsh Rice Trustee Chair of chemical and biomolecular engineering at Rice University

In addition to supporting Amanda Marciel's research, the funds will also go toward creating opportunities in soft matter research for undergraduates and underrepresented scientists at Rice University. Photo by Gustavo Raskosky/Rice University

An assistant professor at Rice University has won one of the highly competitive National Science Foundation's CAREER Awards.

The award grants $670,406 over five years to Amanda Marciel, the William Marsh Rice Trustee Chair of chemical and biomolecular engineering, to continue her research in designing branch elastomers that return to their original shape after being stretched, according to a statement from Rice. The research has applications in stretchable electronics and biomimetic tissues.

“My goal is to create a new paradigm for designing elastomers,” Marciel said in a statement. “The research has four aims: to determine the role of comb polymer topology in forming elastomers, understanding the effects of that topology on elastomer mechanics, characterizing its effects on elastomer structure and increasing the intellectual diversity in soft matter research.” Continue reading.

Youngro Lee, founder of Brassica

Youngro Lee is celebrating the acquisition of his company, Brassica. Photo courtesy

A Houston fintech innovator is celebrating his latest startup's exit.

Brassica Technologies Inc., a fintech infrastructure company that's provides a platform for alternative assets, has been acquired by BitGo, a Palo Alto, California-based tech company with digital asset services. The terms of the deal were not disclosed.

"Joining forces with BitGo is a significant step towards Brassica's ultimate vision of building the financial infrastructure of the future," Youngro Lee, founder and CEO of Brassica, says in a news release. "Our strength lies in our 'one stop shop' approach of providing API-enabled infrastructure for the alternative assets industry. Continue reading.

Four-year-old Brassica has been acquired. Photo via brassicafin.com

Houston fintech startup acquired by California unicorn

M&A moves

A Houston fintech innovator is celebrating his latest startup's exit.

Brassica Technologies Inc., a fintech infrastructure company that's provides a platform for alternative assets, has been acquired by BitGo, a Palo Alto, California-based tech company with digital asset services. The terms of the deal were not disclosed.

"Joining forces with BitGo is a significant step towards Brassica's ultimate vision of building the financial infrastructure of the future," Youngro Lee, founder and CEO of Brassica, says in a news release. "Our strength lies in our 'one stop shop' approach of providing API-enabled infrastructure for the alternative assets industry.

"This sector is rapidly growing and bringing in new investors around the world," Lee continues. "Our technology-focused development, combined with our deep domain expertise in securities and banking laws, uniquely position us in the market, especially for sophisticated clients dealing with the complexities of private securities and digital assets."

Lee founded Brassica in 2020 after his first fintech company, NextSeed, was acquired by Republic. Brassica raised its $8 million seed round led by Houston-based Mercury last year.

The acquisition is a strategic move by BitGo, which was valued at $1.75 billion last year, according to the company after its $100 million raise. Adding Brassica's suite of technology expands on BitGo's ability to grow its customer base.

"We currently have a dichotomy in financial services — one side deals with traditional securities and the other deals with up-and-coming blockchain-based assets and cryptocurrencies," Mike Belshe, CEO of BitGo, says in the release. "With this acquisition, BitGo becomes the first major financial services firm to be able to provide comprehensive infrastructure support for both traditional private securities and blockchain-based assets, while significantly expanding our global presence."

Last year, Lee joined the Houston Innovators Podcast to discuss Brassica and his overarching mission of democratizing fintech and investment tools. He explains there hasn't been a seamless solution created for the backend of alternative asset transactions, things like custody of those assets or transferring and keeping track of them.

"The reason why I thought this was what I wanted to focus on next was exactly because it was an issue I struggled with as a founder of NextSeed," Lee says on the show. "The backend was always an issue. There's not one single vendor that we felt really understood our business, was doing it efficiently, or enabled us to deliver those services to our end clients."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.